High-dose Cytarabine and Mitoxantrone as Salvage Therapy for Refractory Non-Hodgkin's Lymphoma

Japanese Journal of Clinical Oncology

Volumn 27, Issue 3, 1997, Pages 154-157

  Wang, Wei Shu ^a,b   Tzeng, Cheng Hwai ^a   Chiou, Tzeon Jye ^a   Liu, Jin Hwang ^a   Hsieh, Ruey Kuen ^a   Yen, Chueh Chuan ^a   Chen, Po Min ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

High dose ara C; Mitoxantrone; Refractory non Hodgkin's lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; MITOXANTRONE;

ADULT; AGED; BONE MARROW; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; MIDDLE AGED; NEUTROPENIA; NONHODGKIN LYMPHOMA; REMISSION; REVIEW; SALVAGE THERAPY; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOPENIA; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MITOXANTRONE; NEUTROPENIA; REMISSION INDUCTION; SALVAGE THERAPY; THROMBOCYTOPENIA;

EID: 0031156947     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/27.3.154     Document Type: Article

References (26)

1. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993;328:1023-30.
2. Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982;60:693-7
3. Frei E, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med 1980;69:585-94.
4. Kremer WB. Cytarabine. Ann Intern Med 1975;82:684-8.
5. Rudnick SA, Cadman EC, Capizzi RL, Skell RT, Bertino JR, McIntosh S. High dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer 1979;44:1189-93.
6. Gams RA, Steinberg J, Posner L. Mitoxantrone in malignant lymphoma. Semin Oncol 1984;1(suppl 1):47-9.
7. Shenkenberg TD, von Hoff DD. Mitoxantrone: a new anticancer drug with significant clinical activity Ann Intern Med 1986;105:67-81.
8. Ho AD, Valle FD, Ruckle H, Schwammborn J, Schlimok G, Hiddemann Wet al. Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma. Cancer 1989;64:1388-92.
9. Chabner BA, Myers CE, Coleman N, Johns DG. The clinical pharmacology of antmeoplastic agents (second of two parts). N Engl J Med 1975;292:1159-68.
10. Early AP, Preisler HD, Slocum H, Rustum YM. A pilot study of high-dose 1-beta-D-arabinofuransylcytosine for acute leukemia and refractory lymphoma. Clinical response and pharmacology. Cancer Res 1982;42:1587-94.
11. Capizzi RL, Poole M, Copper MR, Richards F, Stuart JJ, Jackson DV et al. Treatment of poor risk acute leukemia with sequential high-dose ara-C and asparaginase. Blood 1984;63:694-700.
12. Breithaupt H, Pralle H, Eckhardt T, von Hattingberg M, Schick J, Loeffler H. Clinical results and pharmacokinetics of high dose cytosine arabinoside (HD ara-C). Cancer 1982;50:1248-57.
13. Rohatiner AZS, Slevin ML, Dhaliwal HS, Malpas JS, Lister TA. High-dose cytosine arabinoside: response to therapy in acute leukemia and non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 1984;12:90-3.
14. Kantarjian H, Barlogie B, Plunkett W, Velasquez W, McLaughlin P. Riggs S et al. High-dose arabinoside in non-Hodgkin's lymphoma. J Clin Oncol 1983,1:689-94.
15. Shipp MA, Takvonan RC, Canellos GP. High-dose cytosine arabinoside: active agent in treatment of non-Hodgkin's lymphoma. Am J Med 1984;77:845-50.
16. Adelstein DJ, Lazarus HM, Hines JD, Herzig RH High-dose cytosine arabinoside in previously treated patients with poor prognosis non-Hodgkin's lymphoma. Cancer 1985;56:1493-6
17. Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, Donhuijsen-Ant R et al. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood 1987;69:744-9.
18. Hines JD, Oken MM, Mazza JJ, Keller AM, Streeter RR, Glick JM. High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic lukemia. J Clin Oncol 1984;2.545-9.
19. Bensinger TA, Fahey JL, Kellon DB, Beutler E. Febrile reaction response to cytarabine. JAMA 1974;229:1578.
20. Slavin RE, Dias MA, Saral R. Cytosine arabinoside induced gastro-intestinal toxic alterations in sequential chemotherapeutic protocols. A clinical-pathologic study of 33 patients. Cancer 1978;42:1747-59.
21. Frick J, Ritch PS, Hansen RM, Anderson T. Successful treatment of meningeal leukemia using systemic high-dose cytosine arabinoside. J Clin Oncol 1984;2.365-8.
22. Lazarus HM, Herzig RH, Herzig GP, Phillips GL, Roessmann U, Fishman DJ. Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer 1981;48:2577-82.
23. Ho AD, Valle FD, Engelhard M, Hiddemann W, Ruckle H, Schlimok G et al. Mitoxantrone/high-dose ara-C and recombinant human GM-CSF in the treatment of refractory non-Hodgkin's lymphoma. Cancer 1990,66-423-30.
24. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ara-C and dexamethasone (DHAP). Blood 1988,71:117-22.
25. Ezzat AA, Khalifa F, Berry J, Khan B, Raja MA, Abdel-Warith A. E-SHAP: an effective treatment in selected patients with relapsed non-Hodgkin's lymphoma. Ann Oncol 1994;5.453-6.
26. Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM et al. EPOCH chempotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993;11:1573-82